search
Back to results

RCT of Sepsis Machine Learning Algorithm

Primary Purpose

Sepsis, Severe Sepsis, Septic Shock

Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
InSight
Sponsored by
Dascena
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Sepsis focused on measuring Dascena, patient mortality, machine learning, algorithm, diagnostic

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • During the study period, all patients over the age of 18 presenting to the emergency department or admitted to an inpatient unit at the participating facilities will automatically be enrolled in the trial, until the enrollment target for the study is met

Exclusion Criteria:

  • Patients under the age of 18

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Experimental

    Control

    Arm Description

    The experimental arm will involve patients monitored by InSight.

    The control arm will have no intervention and will involve patients with the usual standard of care.

    Outcomes

    Primary Outcome Measures

    In-hospital SIRS-based mortality
    Rate of mortality attributed to patients meeting two or more SIRS criteria at some point during their stay

    Secondary Outcome Measures

    Full Information

    First Posted
    March 18, 2019
    Last Updated
    September 17, 2021
    Sponsor
    Dascena
    Collaborators
    University of California, San Francisco
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03882476
    Brief Title
    RCT of Sepsis Machine Learning Algorithm
    Official Title
    Randomized Controlled Trial of a Machine Learning Algorithm for Early Sepsis Detection
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2021
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Study not funded
    Study Start Date
    January 1, 2020 (Anticipated)
    Primary Completion Date
    February 28, 2021 (Anticipated)
    Study Completion Date
    February 28, 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Dascena
    Collaborators
    University of California, San Francisco

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    The focus of this study will be to conduct a prospective, multi-center randomized controlled trial (RCT) at Cape Regional Medical Center (CRMC), Oroville Hospital (OH), and UCSF Medical Center (UCSF) in which a machine-learning algorithm will be applied to EHR data for the detection of sepsis. For patients determined to have a high risk of sepsis, the algorithm will generate automated voice, telephone notification to nursing staff at CRMC, OH, and UCSF. The algorithm's performance will be measured by analysis of the primary endpoint, in-hospital SIRS-based mortality.
    Detailed Description
    From January 2020 to February 2021, inclusive, investigators will perform a multi-center randomized controlled trial (RCT) at CRMC, OH, and UCSF. All aims of this study have been have been submitted for approval by the Pearl Institutional Review Board with a waiver of informed consent. During the study period, all patients over the age of 18 presenting to the emergency department or admitted to an inpatient unit at the participating facilities will automatically be enrolled in the trial, until the target enrollment for the study is met. Enrollment will entail randomization to either the control or the experimental arms. Patients will be assigned to the experimental group or control group based on a random allocation sequence, generated by a computer program before the start of the trial, using simple randomization, with a 1:1 allocation ratio. This allocation sequence will be concealed to patients, healthcare providers and study investigators. However the trial will have an open-label design, as full blinding is not possible as some group assignments will become naturally revealed upon receipt of telephonic alerts. There will be two arms in the study. The control arm will involve patients with the usual standard of care, and the experimental arm will involve patients monitored by InSight. If the applicable algorithm determines a patient to be at a high risk for sepsis, a telephonic alert will be sent to the charge nurse on duty in the patient's current location. Response to alerts will follow the protocol from our previous sepsis clinical trial. The procedure consists of a nurse conducting a patient bedside evaluation to rule out suspected infection. This includes assessment of patient vital signs, EHR notes, and recent laboratory results. If the nurse suspects sepsis, a physician subsequently assesses the patient and, if appropriate, places an order for administration of the standard sepsis treatment bundle. In the administration of clinical trials, some open-label studies are cluster-randomized while others are randomized at an individual patient level. Cluster randomization is frequently used to minimize "contamination" between treatment and control groups, because exposure of providers to patients from both arms in an open-label study often invites unintentional behavioral biases. These biases may cause providers to adjust their interventions in the control group to mimic their actions in the experimental group, thereby masking the intervention's effect and skewing the study results towards the null. Although open-label, cluster-randomized trials are effective in minimizing contamination among groups, they have several significant disadvantages, including greater complexity in design and analysis as well as larger patient enrollment requirements to achieve the same statistical power. Because larger sample sizes often necessitate increases in cost, length, or complexity of a trial, current research has indicated that trialists should use individual randomization if possible due to the drawbacks of cluster allocation. Given these considerations, investigators concluded that individual randomization was the best strategy for the trial, as it affords a significant amount of increase in statistical power and allows each patient outcome to be assessed independently of every other patient. To minimize possible bias, investigators also decided to make the automated phone call text identical in both arms. The successful use of patient-level randomization in a previous sepsis clinical trial conducted by investigators gives confidence in this trial design. After the discharge of the last enrolled patient, investigators will evaluate whether the primary endpoint of in-hospital SIRS-based mortality is met. Additional outcome measures of interest for each SIRS-based group will include: time to completion of each element of the Surviving Sepsis Campaign (SSC) bundle; ventilator-free days; ICU days; and 30-day hospital readmission rate. The 1-hour SSC bundle consists of obtaining blood cultures, measuring lactate level, administering broad-spectrum antibiotics, administering 30 mL/kg of crystalloid fluid for hypertension or lactate >4 mmol/L, and applying vasopressors if patient is hypotensive during or after fluid resuscitation. Investigators plan to draw from EHR-based clinical data for primary endpoint analysis, as opposed to claims-based data, due to its ability to provide more objective measurements on patient outcomes. At the conclusion of the study, significant findings will be published as scientific papers.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Sepsis, Severe Sepsis, Septic Shock
    Keywords
    Dascena, patient mortality, machine learning, algorithm, diagnostic

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Experimental
    Arm Type
    Experimental
    Arm Description
    The experimental arm will involve patients monitored by InSight.
    Arm Title
    Control
    Arm Type
    No Intervention
    Arm Description
    The control arm will have no intervention and will involve patients with the usual standard of care.
    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    InSight
    Intervention Description
    Clinical decision support (CDS) system for sepsis detection
    Primary Outcome Measure Information:
    Title
    In-hospital SIRS-based mortality
    Description
    Rate of mortality attributed to patients meeting two or more SIRS criteria at some point during their stay
    Time Frame
    Through study completion, an average of eight months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: During the study period, all patients over the age of 18 presenting to the emergency department or admitted to an inpatient unit at the participating facilities will automatically be enrolled in the trial, until the enrollment target for the study is met Exclusion Criteria: Patients under the age of 18
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ritankar Das, MSc
    Organizational Affiliation
    Dascena
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    28638239
    Citation
    Desautels T, Calvert J, Hoffman J, Mao Q, Jay M, Fletcher G, Barton C, Chettipally U, Kerem Y, Das R. Using Transfer Learning for Improved Mortality Prediction in a Data-Scarce Hospital Setting. Biomed Inform Insights. 2017 Jun 12;9:1178222617712994. doi: 10.1177/1178222617712994. eCollection 2017.
    Results Reference
    background
    PubMed Identifier
    27253619
    Citation
    Calvert J, Mao Q, Rogers AJ, Barton C, Jay M, Desautels T, Mohamadlou H, Jan J, Das R. A computational approach to mortality prediction of alcohol use disorder inpatients. Comput Biol Med. 2016 Aug 1;75:74-9. doi: 10.1016/j.compbiomed.2016.05.015. Epub 2016 May 24.
    Results Reference
    background
    PubMed Identifier
    27026611
    Citation
    Calvert JS, Price DA, Barton CW, Chettipally UK, Das R. Discharge recommendation based on a novel technique of homeostatic analysis. J Am Med Inform Assoc. 2017 Jan;24(1):24-29. doi: 10.1093/jamia/ocw014. Epub 2016 Mar 28.
    Results Reference
    background
    PubMed Identifier
    27699003
    Citation
    Calvert J, Mao Q, Hoffman JL, Jay M, Desautels T, Mohamadlou H, Chettipally U, Das R. Using electronic health record collected clinical variables to predict medical intensive care unit mortality. Ann Med Surg (Lond). 2016 Sep 6;11:52-57. doi: 10.1016/j.amsu.2016.09.002. eCollection 2016 Nov.
    Results Reference
    background
    PubMed Identifier
    29435343
    Citation
    Shimabukuro DW, Barton CW, Feldman MD, Mataraso SJ, Das R. Effect of a machine learning-based severe sepsis prediction algorithm on patient survival and hospital length of stay: a randomised clinical trial. BMJ Open Respir Res. 2017 Nov 9;4(1):e000234. doi: 10.1136/bmjresp-2017-000234. eCollection 2017.
    Results Reference
    background

    Learn more about this trial

    RCT of Sepsis Machine Learning Algorithm

    We'll reach out to this number within 24 hrs